Patients treated with SGLT2 inhibitors had a significantly lower prevalence of atrial fibrillation at the second admission compared to the control group (OR = 4.773, 95% CI: 2.150 to 10.81, p value < 0.0001). The gene discussed is SLC5A2; the disease is atrial fibrillation.